WHO's cancer research agency bringing global epidemiology, metabolomics, and screening expertise to international prevention-focused consortia.
IARC — the International Agency for Research on Cancer — is the specialized cancer research agency of the World Health Organization, based in Lyon, France. They conduct and coordinate research on the causes of cancer, the mechanisms of carcinogenesis, and develop scientific strategies for cancer prevention and control worldwide. In H2020, IARC contributes epidemiological expertise, large-scale cohort data, biomarker research, and metabolomics capabilities to international consortia focused on cancer prevention, screening, and the impact of environmental exposures on health.
Core contributor across HEADSpAcE (head and neck cancer), EULAT Eradicate GBC (gallbladder cancer), RISCC (cervical cancer screening), CBIG-SCREEN (cervical cancer implementation), and ARICE (cancer research capacity building).
Significant funding in EXPANSE (EUR 1.27M for urban exposome/metabolomics) and HEAP (metabolomics, microbiomics platforms), with metabolomics appearing as a recurring recent keyword.
Participated in B3Africa (bridging biobanking Europe-Africa), ADOPT BBMRI-ERIC (biobank gateway implementation), and ARICE (biobanking for Armenian cancer research).
HPV is a cross-cutting theme in HEADSpAcE (HPV in head and neck cancer), RISCC (risk-based cervical screening), and CBIG-SCREEN (cervical cancer screening for vulnerable women).
Strong global South engagement: B3Africa (Europe-Africa), EULAT Eradicate GBC (Latin America), ARICE (Armenia), and CBIG-SCREEN (vulnerable/migrant populations).
HEAP involves artificial intelligence and big data analytics; EXPANSE uses large-scale data integration for exposome assessment — both from 2020 onwards.
In the early H2020 period (2015–2018), IARC focused on biobanking infrastructure, biospecimen data management, and foundational cancer genetics — building the data backbone for cross-continental research (B3Africa, ADOPT BBMRI-ERIC). From 2019 onward, their work shifted decisively toward applied cancer prevention: risk-based screening models, metabolomics-driven exposure science, wearable sensor platforms, and AI-powered health analytics. This evolution shows a clear trajectory from data infrastructure toward precision prevention and digital health tools.
IARC is moving toward data-intensive, AI-supported cancer prevention — combining metabolomics, environmental exposure monitoring, and predictive modelling to identify cancer risk before disease onset.
IARC operates overwhelmingly as a participant (8 of 9 projects), contributing specialized cancer research expertise to large international consortia rather than leading them. With 111 unique partners across 40 countries, they function as a global hub — their WHO affiliation and worldwide mandate make them a natural connector between European research networks and institutions in Africa, Latin America, and the Caucasus. Their single coordinator role (HEADSpAcE) bridges South America and Europe, reflecting their strength in facilitating cross-continental cancer research collaborations.
IARC has collaborated with 111 unique partners across 40 countries, making them one of the most geographically diverse collaborators in health research. Their network spans well beyond Europe into Africa, Latin America, and Central Asia, reflecting their WHO mandate for global cancer research.
IARC is not just another cancer research institute — it is THE WHO agency for cancer research, giving it unmatched authority, global reach, and access to population-level data across continents. Their ability to bridge European research infrastructure with low- and middle-income countries (Africa, Latin America, Armenia) is rare and valuable for any consortium needing genuine global health impact. For partners, IARC brings both scientific credibility and a ready-made network of health ministries and research institutions worldwide.
